GlassScriptPhysician profile
Jasmine A Ebott
NPI 1952838542
$1,775.48
in general payments reported to CMS, 2019-2025
26 companies · $1,151 in 2025
The $1,151 reported for 2025 was more than what 92% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $242 · 2024: $383 · 2025: $1,151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,651 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,650.78 |
| Education | $124.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $291.16 | 2023-2025 | Jemperli, Zejula |
| Merck Sharp & Dohme LLC | $203.41 | 2024-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Caris Mpi, INC. | $123.82 | 2025 | Mi Cancer Seek |
| Ethicon US, LLC | $109.50 | 2025 | Surgicel Nu-Knit, Ethicon |
| Janssen Biotech, INC. | $103.65 | 2024-2025 | Talvey, Tecvayli, Darzalex |
| Bayer Healthcare Pharmaceuticals INC. | $101.24 | 2024-2025 | |
| Aadi Bioscience, INC. | $99.00 | 2023 | Fyarro |
| Daiichi Sankyo INC. | $85.78 | 2024-2025 | Enhertu |
| Pharmaessentia USA Corporation | $75.82 | 2025 | Besremi |
| Astrazeneca Pharmaceuticals LP | $73.05 | 2023-2025 | Enhertu, Lynparza |
| Sobi, INC | $59.57 | 2024-2025 | |
| Adc Therapeutics America, INC. | $49.84 | 2024-2025 | |
| Agios Pharmaceuticals, INC. | $48.36 | 2024 | Pyrukynd |
| Takeda Pharmaceuticals U.S.A., INC. | $41.00 | 2024-2025 | Fruzaqla |
| Regeneron Healthcare Solutions, INC. | $39.99 | 2024-2025 | Libtayo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $33.95 | 2025 | |
| Genmab U.S., INC. | $33.85 | 2025 | Epkinly |
| Janssen Pharmaceuticals, INC | $29.93 | 2025 | Erleada |
| Exelixis INC. | $28.51 | 2025 | Cabometyx |
| Eisai INC. | $27.16 | 2025 | |
| Lilly USA, LLC | $23.00 | 2025 | Verzenio, Jaypirca |
| Genentech USA, INC. | $21.82 | 2025 | Venclexta |
| Astellas Pharma US INC | $20.12 | 2024 | Vyloy |
| Legend Biotech USA INC. | $19.56 | 2025 | Carvykti |
| Puma Biotechnology, INC. | $17.43 | 2025 | |
| Tactile Systems Technology INC | $14.96 | 2025 | Flexitouch Plus, Nimbl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasmine Ebott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.